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Purpose: The purpose of this study was to evaluate the correlation between the ex-
pression of claudins and prognostic factors in patients with prostate cancer.
Materials and Methods: The subjects of this study were 48 patients who had undergone 
surgery for prostate cancer. The Gleason score (6 or lower, 7 or higher), prostate-specific 
antigen (PSA) level, T stage, biochemical recurrence, local recurrence, and distant 
metastasis were compared according to the expression of claudin-1 and claudin-5 in 
prostate cancer.
Results: In the group with a low expression of claudin-1, the Gleason score was 7 points 
or higher in 18 cases (82%) and 6 points or lower in 4 cases (18%). In the group with 
a high expression of claudin-1, the Gleason score was 7 points or higher in 13 cases (50%) 
and 6 points or lower in 13 cases (50%). Thus, the low-expression group had more cases 
with a Gleason score of 7 or higher (p=0.022). The group with a low expression of claudin- 
5 also had more cases with a Gleason score of 7 or higher (p=0.011). The mean PSA values 
in the groups with a low and high expression of claudin-1 were 9.6 ng/ml and 5.6 ng/ml, 
respectively (p=0.007). A low expression of claudin-5 was also associated with a high 
PSA value (p=0.002). There was no statistical difference in the expression of claudin-1 
and claudin-5 by T stage, biochemical recurrence, local recurrence, or distant meta-
stasis.
Conclusions: The low expression of claudin-1, claudin-5 was associated with a Gleason 
score of 7 or higher and a high PSA value in prostate cancer.
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INTRODUCTION
The incidence of prostate cancer has increased greatly in 
recently years with the popularization of the prostate- 
specific antigen (PSA) test and the increase in the growth 
of the elderly population. According to research, prostate 
cancer is the fifth most frequent malignant tumor in Korean 
men [1]. Most of these tumors are adenocarcinoma, and 
their histological aggressiveness is evaluated by using the 
Gleason grading system, whereby grades are evaluated ac-
cording to changes in glandular architecture. Glandular 
architecture is partly influenced by cellular polarity and 
cell-to-cell contacts, and it could thus be hypothesized that 
changes and dysregulations of proteins mediating cellular 
contacts might influence the histology and Gleason grade 
[1,2].
　The tight junctional proteins located in the apical and ba-
solateral sections of cells act as a gateway and a barrier for 
epithelial and endothelial cells. They separate the lumen 
or glandular architecture in the body from the outside and 
maintain homeostasis and cellular polarity by controlling 
paracellular permeability and osmotic pressure [3-5]. 
Furthermore, they are also known to participate in the con-
trol of the proliferation, differentiation, and functions of 
cells as well as in intercellular communication. 
　The tight junctional proteins consist of three types of in-
tegral membrane proteins: occludins, claudins, and junc-
tional adhesion molecules [6]. Claudins are the tight junc-
tional proteins expressed in epithelial and endothelial cells 
[3,4]. The structural or functional deficiency or loss of these 
proteins is known to be an important process in the develop-
ment and metastasis of cancer [7]. Currently, more than Korean J Urol 2010;51:239-244
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TABLE 1. Clinicopathological characteristics of the patients
Variables
Mean age (years) 63 (51-76)
Mean PSA (ng/ml)    7.4 (3.2-18.4)
No. of patients (%)
Gleason score
  ≤6 17 (35)
  ≥7 31 (65)
T stage
  T2 40 (83)
  T3 8 (17)
  T4 0 (0)
Biochemical recurrence
  No 42 (88)
  Yes 6 (12)
Local recurrence
  No 44 (92)
  Yes 4 (8)
Distant metastasis
  No 44 (92)
  Yes 4 (8)
PSA: prostate-specific antigen
40 tight junctional proteins have been discovered, and 24 
claudins expressed specifically for each tissue are known 
[8]. Because of the abnormal control of claudin proteins, dif-
ferent expression levels of specific claudins have been re-
ported in various tumors, including colorectal cancer [9], 
pancreatic cancer [10], breast cancer [11,12], ovarian can-
cer [13], and prostate cancer [14].
　We investigated the correlation between the expression 
of claudins and prognostic factors  in patients who under-
went surgery for prostate cancer.
MATERIALS AND METHODS
1. Subjects
The subjects of this study were 48 patients with a diagnosis 
of prostate cancer who underwent retropubic radical pro-
statectomy between January 2004 and December 2008. 
The age of the patients, Gleason score, PSA level, T stage, 
biochemical recurrence, local recurrence, and distant meta-
stasis were examined, and the average follow-up period 
was 36 months (range, 12-112 months). One pathologist 
evaluated the stage of the primary tumor and the Gleason 
score of the tumors by observing samples stained with H&E 
under an optical microscope. Biochemical recurrence was 
defined as an increase in PSA above 0.2 ng/ml, twice or more 
in succession, during the follow-up period.
2. Immunohistochemical staining
The pathologist redyed the H&E samples of the subjects to 
mark the representative tumor sites and collected two cores 
with a 3 mm diameter from the paraffin block for each sub-
ject to produce a tissue microarray. The tissue microarray 
paraffin block was cut into 4 μm thick slices, which were 
attached to slides. They were then soaked in xylene for 5 
minutes three times for paraffin removal, passed through 
a moisturizing process, and washed with distilled water. 
For preprocessing for recovery of antigenicity, the citrate 
buffer solution (pH 6.0) was used for the slides for claudin-1 
immunostaining, and the TE buffer solution (pH 9.0) was 
used for the claudin-5 immunostaining. For staining, an 
autostainer (Lab Vision, autostainer360) was used with 
the LP kit (LabVision). For the primary antibody, claudin-1 
(Abcam, #15098) and claudin- 5 (Invitrogen, #18- 7394) 
were diluted to 1:500 and 1:200, respectively, and allowed 
to react for 40 minutes at room temperature. Meyer's hema-
toxylin was used for contrast staining, and an optical micro-
scope was used for observation.
3. Evaluation of immunohistochemical staining
A predominantly membranous pattern of expression was 
observed in the epithelial elements for each of the claudin-1 
and claudin-5 proteins. Immunoreactivity was interpreted 
without prior knowledge of any of the clinicopathologic 
parameters. The intensity and distribution were consid-
ered in the semiquantitative assessment of the mem-
branous staining pattern. The intensity of staining was 
subjectively graded as negative or positive (＋1, weak; ＋2, 
moderate; ＋3, intense; ＋4, strong). Furthermore, the dis-
tribution of staining in the tumor cells was graded as ＋1 
if the distribution of staining was 10% or less in the tumor 
cells, ＋2 if it was 10-50%, ＋3 if it was 50-75%, and ＋4 if 
it was more than 75%. The same weights were given to the 
intensity and distribution of staining, and they were div-
ided into low-expression and high-expression groups on 
the basis of the median value of the sum of these two values.
4. Statistical analysis
The Gleason score (6 or lower, 7 or higher), PSA level, T 
stage, biochemical recurrence, local recurrence, and dis-
tant metastasis were compared according to the expression 
of claudin-1 and claudin-5 in prostate cancer. The chi- 
square test and SPSS version 12.0 (SPSS Inc., Chicago, IL, 
USA) were used for analysis. Statistical significance was 
based on a p-value less than 0.05.
RESULTS
1. Clinicopathologic characteristics
The primary tumors of the patients were staged as follows: 
T2 for 40 cases (83%) and T3 for 8 cases (17%). Gleason 
scores were 6 or lower in 17 cases (35%) and 7 or higher in 
31 cases (65%). The mean PSA was 7.4 ng/ml (range, 
3.2-18.4 ng/ml). Biochemical recurrence was observed in 6 
cases (12%), local recurrence in 4 cases (8%), and distant 
metastasis in 4 cases (8%) (Table 1). The correlation be-
tween claudin expression and PSA and Gleason score are 
summarized in Table 2.
2. Expression profiles of claudin-1
The group with a low expression of claudin-1 consisted of Korean J Urol 2010;51:239-244
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TABLE 2. Claudin expression in prostate adenocarcinoma and in 
relation to Gleason score and PSA value
Variables
Claudin-1 
expression 
Claudin-5 
expression 
Low
(n=22)
High
(n=26)
Low
(n=17)
High
(n=31)
PSA value (ng/ml)
  ＜4 0404
  4-10 15 22 11 26
  ＞1 0 7061
Gleason score
  5＜ 1212
  63 1 1 1 1 3
  7 1 3489
  8 2222
  9 2543
  1 0 1212
PSA: prostate-specific antigen
TABLE 3. Comparison of clinicopathological characteristics 
according to claudin-1 and claudin-5 expression
Variables
Claudin-1 
expression p-
value
Claudin-5 
expression p-
value Low
(n=22)
High
(n=26)
Low
(n=17)
High
(n=31)
Mean PSA (ng/ml) 9.6 5.6 0.007 9.8 6.1 0.002
Gleason score 
≤6 4 13 
0.022
2 15 
0.011
≥7 18 13  15 16
T stage
T2 17  23 
0.442
12 28 
0.112
T3  5 3  5 3 
Biochemical recurrence
No 18  24 
0.274
14 28 
0.425
Yes  4 2  3 3 
Local recurrence
No 20  24 
0.861
15 29 
0.524
Yes  2 2  2 2 
Distant metastasis
No 21  23 
0.382
16 28 
0.649
Yes  1 3  1 3 
PSA: prostate-specific antigen
22 cases (46%), and the group with a high expression of clau-
din-1 consisted of 26 cases (54%). In the group with a low 
expression of claudin-1, 18 cases (82%) had a Gleason score 
of 7 points or higher, and 4 cases (18%) had a score of 6 points 
or lower. In the group with a high expression of claudin-1, 
13 cases (50%) had a Gleason score of 7 points or higher, 
and 13 cases (50%) had a score of 6 points or lower. Thus, 
the low-expression group had more cases with a Gleason 
score of 7 or higher (p=0.022) (Fig. 1). The mean PSA values 
were 9.6 ng/ml and 5.6 ng/ml for the groups with a low and 
high expression of claudin-1, respectively. The mean PSA 
value of the low-expression group was statistically higher 
(p=0.007). T stage (p=0.442), biochemical recurrence (p= 
0.274), local recurrence (p=0.861), and distant metastasis 
(p=0.382) were not significantly different by expression of 
claudin-1 (Table 3).
3. Expression profiles of claudin-5
The group with a low expression of claudin-5 consisted of 
17 cases (35%), and the group with a high expression of clau-
din-5 consisted of 31 cases (65%). In the group with a low 
expression of claudin-5, 15 cases (88%) had a Gleason score 
of 7 points or higher, and 2 cases (12%) had a score of 6 points 
or lower. In the group with a high expression of claudin-5, 
16 cases (52%) had a Gleason score of 7 points or higher, 
and 15 cases (48%) had a score of 6 points or lower. Thus, 
the low-expression group had more cases with a Gleason 
score of 7 or higher (p=0.011) (Fig. 2). The mean PSA values 
were 9.8 ng/ml and 6.1 ng/ml for the groups with a low and 
high expression of claudin-5, respectively. The mean PSA 
value of the low-expression group was statistically higher 
(p=0.002). T stage (p=0.112), biochemical recurrence (p= 
0.425), local recurrence (p=0.524), and distant metastasis 
(p=0.649) were not significantly different by expression of 
claudin-5 (Table 3).
DISCUSSION
It is known that many factors are involved in the develop-
ment, advancement, and metastasis of malignant tumors. 
Among them, disintegration of the cytoskeleton and chan-
ges in intercellular adhesion materials are attracting in-
terest as factors related to the pathogenesis of tumor cells 
and as prognostic factors of cancer. The loss of intercellular 
adhesion in tumor cells is known as an important process 
for the intrusion and metastasis of tumor cells to the pe-
ripheral matrix [7]. 
　Cell binding is involved in the interconnection of cells 
and the maintenance of stable interrelations between cells. 
Components include zonula adherens, desmosomes, zon-
ula occludens, and tight junction [15]. Tight junctional pro-
teins are located in the apical and basolateral sections of 
cells, which play an important part in the maintenance of 
polarity of cells, control of paracellular transportation, and 
barrier functions. The molecular biological structure of the 
tight junction is divided into two groups: integral mem-
brane proteins, which include occludins, claudins, and jun-
ctional adhesion molecules, and peripheral membrane pro-
teins, which include zonulae occludes, cingulin, symple-
kin, pilt, and MAGI-1 [16]. Claudin was first discovered in 
1998,  and at least 24 subtypes have been identified. It has 
been reported that the increased or decreased expression 
of specific claudins influences the development of various 
cancers [8].
　Normal cells distinctively express various claudin pro-
teins, but some subtypes of claudin have tissue-specific 
distributions. Claudin-4 is expressed in lungs and kidney, 
but not in liver. In contrast, claudin-2 is normally ex-Korean J Urol 2010;51:239-244
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FIG. 1. Claudin-1 expression in prostate malignancy tissues (anti-claudin-1 antibody, x400). (A) Loss of membranous claudin-1 
expression in a case of high-grade PCa. (B) High expression of membranous claudin-1 protein in a case of low-grade PCa. PCa: prostate 
cancer.
FIG. 2. Claudin-5 expression in prostate malignancy tissues (anti-claudin-5 antibody, x400). (A) Loss of membranous claudin-5 
expression in a case of high-grade PCa. (B) High expression of membranous claudin-5 protein in a case of low-grade PCa. PCa: prostate 
cancer.
pressed in liver, but not in lungs and kidney. Furthermore, 
claudins exhibit highly tissue-specific distributions by car-
cinoma. Hornsby et al studied the expression of claudin-7 
in renal cell carcinoma (RCC) and reported a higher ex-
pression of claudin-7 in chromophobe RCC than in clear- 
cell RCC and papillary RCC [17]. In a study about the corre-
lation between the expression of claudin-7 and the grade 
of breast cancer, Kominsky et al reported that the low ex-
pression of claudin-7 is associated with the high grade of 
breast cancer [11]. Tokes et al also reported the loss of clau-
din-1 proteins in breast cancer cells and argued that clau-
din-1 is involved in the infiltration and metastasis of breast 
cancer [12]. In a study of the correlation between the ex-
pression of claudin-4 and pancreatic cancer, Nichols et al 
reported a higher expression of claudin-4 in pancreatic can-
cer and metastatic pancreatic cancer tissues than in nor-
mal pancreatic tissues [18]. Lee et al reported that the de-
creased expression of claudin-4 and E-cadherin in gastric 
cancer is associated with oncological low differentiation 
and metastasis [19]. In the case of colorectal cancer, the de-
creased expression of claudin-1 is known to be associated 
with the malignancy of tumors [20]. In addition, many 
studies of the correlation of claudin with ovarian cancer, 
prostate cancer, and other cancers have been conducted 
[13,14]. The correlations between tumors and the ex-
pression of claudin are not uniform, and the expression pro-
files are diverse. 
　Malignant cells are generally known to have structural 
or functional anomalies in tight junctions [21]. This causes 
the loss of cell cohesion and infiltration and a decrease in Korean J Urol 2010;51:239-244
Claudins Expressions and Prognostic Factors 243
differentiation, which influence the infiltration and meta-
stasis of tumor cells to the peripheral matrix. This is sup-
ported by the findings of many studies, i.e., a loss of ex-
pression of tight junctional proteins is evident in carci-
noma. However, the prediction that the progression of an 
infiltrative carcinoma decreases the expression of claudin 
has not been supported in many studies. Choi et al reported 
two reasons the expression of claudin increases in carcino-
ma: first, claudin proteins may increase because of a secon-
dary reaction to the loss of cell adhesion in the process of 
malignant degeneration; second, claudin proteins may in-
crease because of amplification by claudin gene mutation 
[22]. According to various reports, the loss of tight junc-
tional proteins weakens the normal intercellular adhesion 
that separates cancer cells and initiates metastasis. How-
ever, there is doubt about whether the loss of some tight 
junctional proteins affects the change in intercellular ad-
hesion and the differentiation of cancer cells.
　This study found that the low expression of claudin-1 was 
associated with a high Gleason score. The low expression 
of claudin-5 was also found to be associated with a high 
Gleason score. As mentioned above, the Gleason score was 
related to the degree of tumor differentiation and to the for-
mation of glandular architecture in tumors. The disintegra-
tion of glandular architecture and the formation of malig-
nant tumor tissues occur simultaneously, which decreases 
the formation and frequency of tight junctional proteins in 
malignant tumor cells. As a result, the expression of clau-
din seems to decrease in tissues with a high Gleason score. 
In both the claudin-1 and claudin-5 groups, no correlations 
were found with prognostic factors such as T stage, bio-
chemical recurrence, local recurrence, and distant meta-
stasis. However, many previous studies reported a correla-
tion between prognostic factors of prostate cancer and the 
abnormal expression of claudin. Regarding the correlation 
between prostate cancer and abnormal expression of clau-
din-1, -2, -3, -4, -5, and -7, Väre et al reported that the low 
expression of claudin-1 and claudin-5 was strongly corre-
lated with Gleason scores of 7 or higher, as was observed 
in the present study [2]. Furthermore, Väre et al reported 
that the low expression of both claudin-1 and claudin-5 was 
associated with a high TNM stage or local advanced cancer. 
In a study of the correlation between the abnormal expre-
ssion of claudin-1, -3, -4, and -7 and the prognostic factors 
of prostate cancer, Sheehan et al reported that the de-
creased expression of claudin-1 and -7 was associated with 
tumors with histological low differentiation, and a decrea-
sed expression of claudin-1 was associated with biochemi-
cal recurrence [23]. On the other hand, they reported that 
the increased expression of claudin-3 and claudin-4 was as-
sociated with high-stage or advanced tumors and found 
through multivariate analysis that the decreased expre-
ssion of claudin-1 was a predictive factor that was indepen-
dent of the recurrence of tumor. According to Landers et al, 
compared with prostatic hyperplasia tissues, the expre-
ssion of claudin-4 was high in prostate cancer and meta-
static prostate carcinoma [24]. Furthermore, they reported 
that the increased expression of claudin-4 is a useful in-
dicator of cancer diagnosis and is a therapeutic target for 
metastatic prostate carcinoma [24].
　This study found that the PSA value in the groups with 
a low expression of claudin-1 and claudin-5 was statisti-
cally significantly higher than that in the high-expression 
group. Few studies of the correlation between the PSA val-
ue and the expression of claudin have been conducted. 
Zheng et al reported that claudin-7 controls the expression 
of PSA [25]. In a study of the correlation between prostate 
cancer and the abnormal expression of claudin-1, -2, -3, -4, 
-5, and -7, Väre et al reported that in all claudins, the PSA 
value of the low-expression group (i.e., the group with a low 
immunohistochemical score) was higher than that of the 
high-expression group (83.3±87.3 ng/ml vs. 32.9±41.1 ng/ 
ml, p=0.01) [2]. They stated that the low concentration of 
claudin in prostate cancer tissues caused the outflow of 
more tumor cells, which increased the PSA value. 
　As mentioned above, many studies have reported on the 
specific expression of claudins in prostate cancer, and the 
results of our study also support the findings of these pre-
vious studies. However, unlike previous studies, our study 
found no correlation of claudin expression with prognostic 
factors of prostate cancer, such as T stage, biochemical re-
currence, local recurrence, and distant metastasis. The 
reason for this seems to be the small number of cases and 
the difficulty of investigating the patients' prognosis be-
cause of the short follow-up period of this study. Therefore, 
a long-term study with more patients is required.
CONCLUSIONS
The low expression of claudin-1 and claudin-5 was asso-
ciated with a Gleason score of 7 or higher and with a high 
PSA value in prostate cancer. Therefore, it is believed that 
a loss of these proteins would affect the development, pro-
gression, and prognosis of prostate cancer. More long-term 
studies are required to reveal the correlation between clau-
dins and the prognostic factors of prostate cancer.
Conflicts of Interest
The authors have nothing to disclose.
REFERENCES
1. Oliver SE, May MT, Gunnell D. International trends in prostate- 
cancer mortality in the "PSA ERA". Int J Cancer 2001;92:893-8.
2. Väre P, Loikkanen I, Hirvikoski P, Vaarala MH, Soini Y. Low clau-
din expression is associated with high Gleason grade in prostate 
adenocarcinoma. Oncol Rep 2008;19:25-31.
3. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 
and -2: novel integral membrane proteins localizing at tight junc-
tions with no sequence similarity to occludin. J Cell Biol 1998;141: 
1539-50.
4. Tsukita S, Furuse M. Claudin-based barrier in simple and strati-
fied cellular sheets. Curr Opin Cell Biol 2002;14:531-6.
5. Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima 
T, et al. Tight junctions and human diseases. Med Electron Korean J Urol 2010;51:239-244
244 Seo et al
Microsc 2003;36:147-56.
6. Matsuda M, Kubo A, Furuse M, Tsukita S. A peculiar internal-
ization of claudins, tight junction-specific adhesion molecules, 
during the intercellular movement of epithelial cells. J Cell Sci 
2004;117:1247-57.
7. Jiang WG, Puntis MC, Hallett MB. Molecular and cellular basis 
of cancer invasion and metastasis: implications for treatment. Br 
J Surg 1994;81:1576-90.
8. Turksen K, Troy TC. Barriers built on claudins. J Cell Sci 
2004;117:2435-47. 
9. Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y, Furukawa 
Y. Involvement of claudin-1 in the bata-catenin/Tcf signaling 
pathway and its frequent upregulation in human colorectal 
cancers. Oncol Res 2001;12:469-76.
10. Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, 
Saito K, et al. Distinct expression patterns of claudin-1 and clau-
din-4 in intraductal papillary- mucinous tumors of the pancreas. 
Pathol Int 2005;55:63-9.
11. Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, 
et al. Loss of the tight junction protein claudin-7 correlates with 
histological grade in both ductal carcinoma in situ and invasive 
ductal carcinoma of the breast. Oncogene 2003;22:2021-33.
12. Tokes AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, et al. 
Claudin-1, -3 and -4 proteins and mRNA expression in benign and 
malignant breast lesions: a research study. Breast Cancer Res 
2005;7:R296-305.
13. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, 
Rosenshein NB, et al. Large-scale serial analysis of gene ex-
pression reveals genes differentially expressed in ovarian cancer. 
Cancer Res 2000;60:6281-7.
14. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG. 
Expression of Clostridium perfringens enterotoxin receptors 
claudin-3 and claudin-4 in prostate cancer epithelium. Cancer 
Res 2001;61:7878-81.
15. Gumbiner BM. Cell adhesion: the molecular basis of tissue archi-
tecture and morphogenesis. Cell 1996;84:345-57.
16. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight 
junction proteins. Prog Biophys Mol Biol 2003;81:1-44.
17. Hornsby CD, Cohen C, Amin MB, Picken MM, Lawson D, 
Yin-Goen Q, et al. Claudin-7 immunohistochemistry in renal tu-
mors: a candidate marker for chromophobe renal cell carcinoma 
identified by gene expression profiling. Arch Pathol Lab Med 
2007;131:1541-6.
18. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein 
expression in primary and metastatic pancreatic cancer: support 
for use as a therapeutic target. Am J Clin Pathol 2004;121:226-30.
19. Lee SM, Lee JH, Kim BG, Kim YS, Park YG, Chi KC, et al. 
Correlation of decreased expressions of claudin 4 and E-cadherin 
proteins and the clinicopathologic factors of stomach cancer. J 
Korean Surg Soc 2007;73:221-6.
20. Tokés AM, Kulka J, Paku S, Máthé M, Páska C, Lódi C, et al. The 
expression of five different claudins in invasive breast carcino-
mas: comparison of pT1pN1 and pT1pN0 tumors. Pathol Res 
Pract 2005;201:537-44.
21. Soler AP, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin 
JM. Increased tight junctional permeability is associated with the 
development of colon cancer. Carcinogenesis 1999;20:1425-31.
22. Choi HJ, Jung JH, Yoo J, Kang SJ, Lee KY. Expression of clau-
din-1 and -4 in benign lesions and invasive ductal carcinomas of 
the breast. Korean J Pathol 2007;41:232-7.
23. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman 
RP Jr, Ross JS. Loss of claudins-1 and -7 and expression of clau-
dins-3 and -4 correlate with prognostic variables in prostatic 
adenocarcinomas. Hum Pathol 2007;38:564-9.
24. Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells 
B, et al. Identification of claudin-4 as a marker highly overex-
pressed in both primary and metastatic prostate cancer. Br J 
Cancer 2008;99:491-501.
25. Zheng JY, Yu D, Foroohar M, Ko E, Chan J, Kim N, et al. 
Regulation of the expression of the prostate-specific antigen by 
claudin-7. J Membr Biol 2003;194:187-97.